

Supplementary Tables have been published as submitted. They have not been copyedited, typeset or checked for scientific content by Acta Dermato-Venereologica

Table SI. Demographic data for the 34 pediatric vitiligo patients

Characteristic	Result	<i>P</i> value
Onset age, yr (SD)		
Mean (range)	5.0 ± 3.3 (1.0 – 15.0)	
Age, yr		
Mean (range)	9.9 ± 4.7 (3.0 – 20.0)	
Sex, no. (%)		0.039*
Male	11 (32.4%)	
Female	23 (67.6%)	
Location of vitiligo lesion, no. (%)		0.038*
Frontal	16 (35.6%)	
Vertex	16 (35.6%)	
Occipital	8 (17.8%)	
Temporal	5 (11.1%)	
Number of lesions, no. (%)		<0.001*
Single	27 (79.4%)	
Multiple	7 (20.6%)	
Extra-scalp lesions, no. (%)		0.053‡
Face	8 (23.5%)	
Trunk	4 (11.4%)	
Extremity	2 (5.7%)	
Multiple	1 (2.9%)	
None	19 (55.9%)	
Duration of illness, yr		
Mean (range)	4 (0 – 15)	
Comorbidities, no. (%)		
Dermatologic	4 (11.4%)‡	
Non-dermatologic	1 (2.9%)‡‡	
Family history of vitiligo	0	

* $P < 0.05$ was considered statistically significant.

‡ P value was computed excluding patients without any extra-scalp lesions.

‡ Includes morphea (n=1), alopecia areata (n=2), and atopic dermatitis (n=1)

‡‡ Includes osteosarcoma

The format and content has not been edited by ActaDV.

Table S2. Analysis of prognoses in 25 patients with sufficient follow-up and potentially related variables

	Outcome of patients		
	Worsened	Not worsened	
Mean of onset age, yr	5	5	0.7
Number of lesions			0.13
Single (n=20)	7	13	
Multiple (n=5)	4	1	
Extra-scalp lesion			0.047*
At least one (n=12)	8	4	
None (n=13)	3	10	
Treatment			
Observation (n=2)	0	2	0.49
Topical therapy (n=22) ¶	10	12	1.0
Systemic steroid (n=5) ¶¶	3	2	0.62
Excimer laser (n=15) ¶¶¶	7	8	1.0

* $P < 0.05$ was considered statistically significant.

¶ Including patients treated with a topical steroid and/or topical calcineurin inhibitor twice a day for at least 4 weeks

¶¶ Including patients treated with oral prednisolone or its equivalents at 5 mg or higher per day for at least 1 week

¶¶¶ Including patients treated with an excimer laser twice a week starting from a dosage of 80 mJ/cm²